Effectiveness of Proton Pump Inhibitors in Nonerosive Reflux Disease

被引:391
作者
Dean, Bonnie B. [1 ]
Gano, Anacleto D., Jr. [1 ]
Knight, Kevin [1 ]
Ofman, Joshua J. [1 ,2 ]
Fass, Ronnie [3 ]
机构
[1] Cerner Hlth Insights, Beverly Hills, CA USA
[2] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
[3] So Arizona VA Hlth Care Syst, Tucson, AZ USA
关键词
D O I
10.1016/S1542-3565(04)00288-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Little information is available about the efficacy of proton pump inhibitors (PPIs) in patients with nonerosive reflux disease (NERD). We aimed to synthesize available data and determine the effectiveness of PPIs on symptom resolution in patients with NERD. Methods: A systematic review of the literature identified studies reporting the effects of PPIs in patients with NERD. Heartburn resolution data were pooled across studies. The effectiveness of PPI therapy in inducing complete heartburn resolution was compared in patients with NERD vs. erosive esophagitis (EE). Results: Seven trials evaluating heartburn resolution in NERD were identified. Higher proportions of patients reported achieving sufficient heartburn resolution compared with complete heartburn resolution. The effect of PPIs on sufficient heartburn resolution was observed sooner than was complete heartburn resolution. Therapeutic gain of PPI therapy over placebo ranged from 30% to 35% for sufficient heartburn control and from 25% to 30% for complete heartburn control. Pooled response rates at 4 weeks were significantly higher for patients with EE compared with NERD (56% vs. 37%, P < 0.0001). Conclusions: PPIs provide a more modest therapeutic gain in patients with NERD as compared with those with EE. A trend in increased therapeutic gain for NERD patients was shown throughout the 4 weeks, suggesting that 4 weeks of follow-up evaluation may be insufficient to show full therapeutic gain in this patient population.
引用
收藏
页码:656 / 664
页数:9
相关论文
共 30 条
[1]  
AstraZeneca, 1999, 21153226 FDA ASTRAZE
[2]  
AstraZeneca, 1999, 21153225 FDA ASTRAZE
[3]   Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis [J].
Bate, CM ;
Griffin, SM ;
Keeling, PWN ;
Axon, ATR ;
Dronfield, MW ;
Chapman, RWG ;
ODonoghue, D ;
Calam, J ;
Crowe, J ;
Mountford, RA ;
Watts, DA ;
Taylor, MD ;
Richardson, PDI .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (04) :547-555
[4]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[5]   Rabeprazole in treatment of acid peptic diseases - Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) [J].
Cloud, ML ;
Enas, N ;
Humphries, TJ ;
Bassion, S .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (05) :993-1000
[6]  
Fass R, 2001, AM J GASTROENTEROL, V96, P303
[7]  
Fass R, 2002, AM J GASTROENTEROL, V97, P1901
[8]   Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease [J].
Fass, R .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :S2-S7
[9]   Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride [J].
Galmiche, JP ;
Barthelemy, P ;
Hamelin, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (04) :765-773
[10]  
GREEN JRB, 1993, EUR J CLIN RES, V4, P29